PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28073841-8	2017	Data from tumor xenograft mouse models confirmed that everolimus-resistant cancer cells are sensitive to alisertib.Conclusions: Our results indicate that AURKA plays an important role in the activation of EIF4E and cap-dependent translation.	MLN 8237	105-114	eukaryotic translation initiation factor 4E	Mus musculus	205-210	
28073841-9	2017	Targeting the AURKA-EIF4E-c-MYC axis using alisertib is a novel therapeutic strategy that can be applicable for everolimus-resistant tumors and/or subgroups of cancers that show overexpression of AURKA and activation of EIF4E and c-MYC.	MLN 8237	43-52	eukaryotic translation initiation factor 4E	Mus musculus	20-25	
28073841-9	2017	Targeting the AURKA-EIF4E-c-MYC axis using alisertib is a novel therapeutic strategy that can be applicable for everolimus-resistant tumors and/or subgroups of cancers that show overexpression of AURKA and activation of EIF4E and c-MYC.	MLN 8237	43-52	eukaryotic translation initiation factor 4E	Mus musculus	220-225